A Repeatability Study of Fatty Acid Uptake Using PET/MR Imaging in Patients With T2DM and Non-diabetic Control Subjects

NCT ID: NCT05132335

Last Updated: 2023-08-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-29
• Study Completion Date: 2022-04-30

Brief Summary

The main purpose of this study is to evaluate the overall variation in the assessment of fatty acid uptake and blood flow in adipose tissue and skeletal muscle in the fasted and postprandial states by evaluating the repeatability of whole-body three-dimensional kinetic (4D) combined positron emission tomography and magnetic resonance imaging (PET/MRI) readouts in participants with type 2 diabetes mellitus (T2DM), and non-diabetic control participants. Each volunteer participates 4 scanning sessions.

Detailed Description

A total of approximately 13 T2DM and 6 control subjects (a total of 19 subjects) are planned to be enrolled to achieve 11 T2DM and 5 control subjects to complete the study, assuming a 15% drop-out rate. The test-retest repeatability of the ratio of FTHA uptake rates in subcutaneous adipose tissue (SAT) to skeletal muscle is measured using the intra-class correlation coefficient (ICC). Assuming an ICC of 0.85, with a 5% two-sided type I error rate, a sample size of 16 completers will yield approximately 90% power to detect an ICC statistically significantly greater than 0.4 (usually considered as a criterion for moderate agreement).

The total radiaooin burden for tshi sitdu yis 27.4 mSv. The study is approved by the local Ethical committtee and Fimea.

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Experimental: Imaging Biomarkers

Each study subject is is studied in four session: twice after overnight fast and twice after liquid meal injestion using PETMRI imaging. Adipose and skeletal muscle pefusion and fatty adic uptake are measured and and the repeability of results tested for these two situations. In PEt studies PET/MRI Scan with radioactive water (\[15O\]-H2O) and \[18F\]-FTHA are used as tracers. In this experimental study number of subjects studied is rather small. Therefore volunteers with and without T2 diabetes are analysed together and not on different arms.

Group Type: EXPERIMENTAL

Imaging Biomarkers

Intervention Type: OTHER

One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA([18F]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water([15O]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.

Assigned interventions:

[18F]-FTHA tracer injections [15O]-H2O tracer injections

PET/MRI imaging

Overnight fasting Liquid meal ingestion

Interventions

Imaging Biomarkers

One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA([18F]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water([15O]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.

Assigned interventions:

[18F]-FTHA tracer injections [15O]-H2O tracer injections

PET/MRI imaging

Overnight fasting Liquid meal ingestion

Intervention Type: OTHER

Other Intervention Names

Assessment of repeatability of fatty acid uptake in adipose using PETMRI

Eligibility Criteria

Inclusion Criteria

• Have a body mass index (BMI) between 25 to 40 kilograms per meter squared (kg/m²),
• For participants with a confirmed type 2 diabetes diagnosis: The condition must be managed either by diet and exercise alone or on a stable dose of metformin
• For nondiabetic subjects: participants must agree to keep their diet and physical activity habits stable throughout the study
• Female participants must be post-menopausal and male participants

Exclusion Criteria

• Poorly controlled diabetes
• Unstable body weight within 30 days prior to screening.
• For non-diabetic control subjects: evidence of diabetes or prediabetes at screening.
• Having worked as a metal worker or welder
• History of alcohol or drug abuse within 5 years of the screening
• Currently participating, or previous participation in another clinical trial within 30 days prior to the screening visit, or previous participation in another PET imaging study within 12 months.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Antaros Medical

INDUSTRY

Sponsor Role: collaborator

Turku University Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pirjo R Nuutila, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Turku PET Centre

Locations

Turku PET Centre

Turku, , Finland

Turku PET Centre (Turku University Hospital)

Turku, , Finland

Countries

Finland

References

Aarnio R, Kirjavainen A, Rajander J, Forsback S, Kalliokoski K, Nuutila P, Milicevic Z, Coskun T, Haupt A, Laitinen I, Haaparanta-Solin M. New improved radiometabolite analysis method for [18F]FTHA from human plasma: a test-retest study with postprandial and fasting state. EJNMMI Res. 2024 Jun 13;14(1):53. doi: 10.1186/s13550-024-01114-5.

Reference Type: DERIVED

PMID: 38869780 (View on PubMed)

Other Identifiers

AM05

Identifier Type: -

Identifier Source: org_study_id